SecBot SecBot
PRESS-RELEASE ·Filed Apr 28, 2026

EBS

Emergent BioSolutions
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The $34.5M deal is a modest but positive step for Emergent's contract manufacturing business, leveraging the Canton facility's clean regulatory status. However, the vaccine is not yet FDA-approved, and U.S. government distribution revenue is contingent on that approval. Monitor for FDA submission progress and any additional manufacturing partnerships that could further utilize Canton capacity.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.23
T+0 close · Apr 28, 2026 · via day close
Latest settled
−8.87%
T+60 · $7.50
Vs SPY
−12.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $8.23entry
  2. T+1 · 7mo ago −2.92%α −2.91% · $7.99
  3. T+5 · 7mo ago +3.77%α +2.07% · $8.54
  4. T+20 · 6mo ago +10.94%α +5.47% · $9.13
  5. T+60 · 4mo ago −8.87%α −12.86% · $7.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Emergent BioSolutions announced a ~$34.5M agreement with Substipharm Biologics to manufacture drug substance for the IMOJEV Japanese Encephalitis vaccine at its Canton, MA facility and to serve as exclusive U.S. government distributor upon FDA approval. The deal leverages Emergent's recently cleared Canton facility (FDA 'No Action Indicated' status) and provides a new revenue stream, but the vaccine is not yet FDA-approved and the total value is modest relative to EBS's $415M market cap.

Key Financial Metrics

Deal Value
$34.5M

Key Facts

  • Agreement valued at approximately $34.5 million.
  • Emergent will manufacture IMOJEV drug substance at its Canton, MA facility.
  • Emergent will be exclusive distributor of IMOJEV to the U.S. government upon FDA approval.
  • Canton facility received FDA 'No Action Indicated' status after February 2026 inspection.
  • IMOJEV is not yet approved for use in the U.S.; regulatory submission to FDA is pending.
  • Emergent plans to hire additional employees at Canton facility later this year.
  • Substipharm acquired IMOJEV in 2022; vaccine has been used in Asia since 2012.

Financial Impact

~$34.5 million total agreement value, with manufacturing and potential distribution revenue contingent on FDA approval.

revenue

Risk Factors

  • IMOJEV is not FDA-approved; regulatory timeline and approval are uncertain.
  • U.S. government distribution revenue is contingent on FDA approval and may take years to materialize.
  • The $34.5M deal value is small relative to Emergent's $415M market cap, limiting near-term financial impact.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3282615

Track record

23 reports on EBS

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
  4. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
  5. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
  6. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
  8. Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
  10. Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026